Bio-techne Stock News

Exchange Traded Concepts LLC lowered its stake in Bio-Techne Co. (NASDAQ:TECH) by 85.9% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 190 shares of the biotechnology companys stock after selling 1,153 shares during the period. Exchange Traded Concepts LLCs holdings []

Raymond James Trust N.A. lessened its position in shares of Bio-Techne Co. (NASDAQ:TECH) by 9.7% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,437 shares of the biotechnology companys stock after selling 155 shares during the quarter. Raymond James Trust N.A.s []

Legacy Capital Partners Inc. bought a new stake in Bio-Techne Co. (NASDAQ:TECH) in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 415 shares of the biotechnology companys stock, valued at approximately $201,000. Other hedge funds and other institutional investors also recently []

Ritholtz Wealth Management acquired a new stake in Bio-Techne Co. (NASDAQ:TECH) during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 505 shares of the biotechnology companys stock, valued at approximately $245,000. A number of other institutional investors have also made changes []

Wall Street analysts expect Bio-Techne Co. (NASDAQ:TECH) to announce $267.04 million in sales for the current fiscal quarter, according to Zacks. Three analysts have issued estimates for Bio-Technes earnings, with the highest sales estimate coming in at $268.70 million and the lowest estimate coming in at $263.81 million. Bio-Techne posted sales of $224.25 million during []

Equities research analysts expect Bio-Techne Co. (NASDAQ:TECH) to post $1.82 earnings per share for the current quarter, according to Zacks Investment Research. Three analysts have made estimates for Bio-Technes earnings. The highest EPS estimate is $1.87 and the lowest is $1.78. Bio-Techne reported earnings of $1.62 per share in the same quarter last year, which []

Louisiana State Employees Retirement System trimmed its stake in Bio-Techne Co. (NASDAQ:TECH) by 76.2% in the 3rd quarter, HoldingsChannel reports. The firm owned 2,400 shares of the biotechnology companys stock after selling 7,700 shares during the period. Louisiana State Employees Retirement Systems holdings in Bio-Techne were worth $1,163,000 as of its most recent filing with []

Outlook Therapeutics (NASDAQ:OTLK) and Bio-Techne (NASDAQ:TECH) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, earnings, dividends, institutional ownership, valuation, profitability and analyst recommendations. Valuation and Earnings This table compares Outlook Therapeutics and Bio-Technes revenue, earnings per share (EPS) and valuation. []

Bio-Techne Co. (NASDAQ:TECH) has been assigned a consensus rating of Buy from the nine analysts that are currently covering the stock, Marketbeat reports. Two equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. The average twelve-month price target among brokers that have covered []

Bio-Techne Co. (NASDAQ:TECH) insider Kim Kelderman sold 500 shares of the company’s stock in a transaction that occurred on Friday, November 19th. The shares were sold at an average price of $505.38, for a total value of $252,690.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed […]

MINNEAPOLIS, Nov. 22, 2021 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that it will present at two upcoming investor conferences. Chuck Kummeth, President and Chief Executive

Baron funds took big stakes in Nvidia, Sea, Shopify and other companies in the third quarter.

Smart Beta ETF report for PBE

Tissue Microarray (TMA) refers to the innovative practice of relocating multiple tissues sections from conventional histologic paraffin blocks so that the tissues from multiple samples can be observed on the same slide.It is a novel and useful tool to efficiently